India Won’t Be Immune To U.S., China Trade Blows
One of the big immediate risks of the U.S.-China trade war for India and a number of other countries may be “trade diversion”.
That means products and merchandise, hit with retaliatory or counter-retaliatory tariffs by the U.S. and China respectively, will get diverted or even dumped on markets like India, Raj Bhala, Professor at Kansas University told BloombergQuint in an interview. “So the likes of India and Canada have already started to consider the trade defence instruments they might use against this prospect,” he added.
The longer-term impact may be recessionary, Bhala warned. “There is the possibility of a recession, or a drop in jobs, incomes or retaliation by other countries or defence of protectionism by other countries and then you get an area of deflation and possibly recession.”
The trade dispute between the U.S. and China has entered a new phase with the Trump administration announcing higher tariffs on $34 billion of Chinese imports, and an equivalent response from Beijing. Without talks, in the next two weeks or so, the U.S. will announce a further $16 billion of goods to be hit with higher duties, and China is expected to retaliate.
To with the impact on India will be marginal, according to Ajay Dua, former Secretary in the Ministry of Industry and Commerce. But Asia's third-largest economy won't be able to escalate the collateral damage as the conflict escalates, he warned.
Right now we may not be worried about it but we can't keep ourselves totally immune from it.Ajay Dua, Former Secretary, Ministry of Industry and Commerce
Watch the entire conversation here:
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.
-
Why Amazon And Flipkart Are Struggling To Beat Meesho In India's Smaller Cities
With 274 million users and lowest-cost logistics, Meesho is defending its value commerce crown against giants like Amazon and Flipkart.
-
High US Salaries, No Green Card Certainty: The Financial Calculation Facing Indian H-1B Families
The suspension of PERM processing at eight technology employers does not cancel existing H-1B visas. What it does is force a question many Indian families have been avoiding: is the US salary worth tying your career and family plans to one employer?
-
Swiggy vs Eternal: Food Delivery's Two Rivals Are No Longer In The Same Race
Eternal is building a private AI assistant, dark.ai. Swiggy is still working out how to make Instamart pay, with an operating loss of Rs 895 crore in the July-September quarter while Blinkit stayed profitable.
-
Where You Live Shapes How You Get To Work | The Reason Why
Two-wheelers are the most popular way to get to work in India, accounting for nearly 43% of workplace commutes.
-
Unhedged Position: Can India See An Indonesia-Style Time Correction?
The Nifty is trading below levels it first clocked in 2024. Is there, then, as I have suggested in the headline, potential that the current time correction drags on painfully for the next three-five, even ten years?
-
Navigating Friction And Energy Realities: An Analysis Of Marco Rubio's October Visit To India
Occurring at a critical juncture marked by stalled trade negotiations and escalating geopolitical pressures over global energy supplies, the visit offers a profound window into modern US-India relations.
-
India Exports Capital. Why Not Export Trusteeship?
The big question, then, is whether India can build an institution that global borrowers, investors, banks, and lawyers can trust, even without an Indian connection.
-
France's Economy & Politics Are In Crisis | The Reason Why
Let's look at how the French economy and politics evolved under Nicolas Sarkozy, Franois Hollande and Emmanuel Macron.